Cancer Trials Ireland is seeking new Board members.

If you are interested in joining the Board, send an email expressing your interest to karen.munnelly@cancertrials.ie by 5pm September 23rd 2020.

What does the Board do?

The Board is responsible for providing strategic leadership, governance and oversight for the entire organisation with a view to furthering the mission of Cancer Trials Ireland and to promote achievement of excellence in cancer research. It is the decision-making authority of the organisation and is accountable and responsible for the performance of the GCO and the distribution of the grant funds. The Board elects a Chairperson who is independent of Operations. The Clinical Lead and Vice Clinical Lead are on the Board and the Chief Executive Officer attends Board meetings.

Commitment

The Board meets at least five times per year. Membership of the Board is a serious, significant commitment and responsibility. Board members are often requested to join sub-committees of the Board, e.g. Audit Committee, Nominations & Governance Committee, Patient Consultant Committee.

How are Board members selected?

Nominations must be proposed and seconded by Cancer Trials Ireland members. Thereafter, nominations are forwarded to the Nominations & Governance Committee to be reviewed in the context of diversity (see: Diversity Policy below). Once approved, nomination will be added to the ballot for election by the members at the Annual General Meeting (late October 2020, date TBC).

Diversity policy

Cancer Trials Ireland recognises and embraces the benefits of having a diverse Board, and sees increasing diversity at board level as an essential element in succeeding in its purpose. A truly diverse Board will include and make good use of differences in the skills, experience, background, gender and other distinctions between Directors. These differences will be considered in determining the optimum composition of the Board and when possible should be balanced appropriately. All board appointments are made on merit, in the context of the skills, experience, independence and knowledge which the board as a whole requires to be effective. The skills and experience should include clinical research, finance, legal, advocacy, organisational strategy and governance. In order to avoid any potential conflicts of interest no individual who is in a position to receive funding from Cancer Trials Ireland shall serve on the board with the exception of the Clinical Lead and Deputy Clinical Lead both of whom must serve in an ex officio position.

The Board Nominations Committee (‘the Committee’) reviews and assesses Board composition on behalf of the Board and recommends the appointment of new Directors. The Committee also oversees the conduct of the annual review of Board effectiveness.

  • In reviewing Board composition, the Committee will consider the benefits of all aspects of diversity including, but not limited to, those described above, in order to enable it to discharge its duties and responsibilities effectively.
  • In identifying suitable candidates for appointment to the Board, the Committee will consider candidates on merit against objective criteria and with due regard for the benefits of diversity on the Board.
  • As part of the annual performance evaluation of the effectiveness of the Board, Board Committees and individual Directors, the Committee will consider the balance of skills, experience, independence and knowledge of on the Board and the diversity representation of the Board, including gender, how the Board works together as a unit, and other factors relevant to its effectiveness.

Declaring conflicts of interest

Board members must complete a disclosures form detailing any actual / potential conflicts of interest. You can review that form here.

Other information